Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Beckmann

Showing results (741-750 of 1,041) with videos related to

Pageof 105
Sort By:
Breast Cancer Research : BCR|September 20, 2015
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trialPeter Widschwendter, Thomas Wp Friedl, Lukas Schwentner, et al.
Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.
Breast Cancer Research : BCR|April 12, 2012
Characterizing mammographic images by using generic texture featuresLothar Häberle, Florian Wagner, Peter A Fasching, et al.
Journal of Medical Genetics|February 1, 2011
High incidence of recurrent copy number variants in patients with isolated and syndromic Müllerian aplasiaSerena Nik-Zainal, Reiner Strick, Mekayla Storer, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A StudyA Hein, B Rack, L Li, et al.
Geburtshilfe Und Frauenheilkunde|July 31, 2018
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansPaul Gass, Michael Untch, Volkmar Müller, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Hormone Therapy and its Effect on the Prognosis in Breast Cancer PatientsC Rauh, F Schuetz, B Rack, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
Pageof 105

Showing results (741-750 of 1,041) with videos related to

Sort By:
Pageof 105
Breast Cancer Research : BCR|September 20, 2015
The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trialPeter Widschwendter, Thomas Wp Friedl, Lukas Schwentner, et al.
Journal of the National Cancer Institute|October 13, 2018
Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and PrognosisElisabeth Trapp, Wolfgang Janni, Christian Schindlbeck, et al.
Breast Cancer Research : BCR|April 12, 2012
Characterizing mammographic images by using generic texture featuresLothar Häberle, Florian Wagner, Peter A Fasching, et al.
Journal of Medical Genetics|February 1, 2011
High incidence of recurrent copy number variants in patients with isolated and syndromic Müllerian aplasiaSerena Nik-Zainal, Reiner Strick, Mekayla Storer, et al.
Geburtshilfe Und Frauenheilkunde|August 1, 2017
Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A StudyA Hein, B Rack, L Li, et al.
Geburtshilfe Und Frauenheilkunde|July 31, 2018
Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among PhysiciansPaul Gass, Michael Untch, Volkmar Müller, et al.
Plos One|June 7, 2017
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trialB A S Jaeger, J Neugebauer, U Andergassen, et al.
Geburtshilfe Und Frauenheilkunde|July 14, 2015
Hormone Therapy and its Effect on the Prognosis in Breast Cancer PatientsC Rauh, F Schuetz, B Rack, et al.
The Lancet. Oncology|November 28, 2017
Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trialSara A Hurvitz, Miguel Martin, W Fraser Symmans, et al.
Oncology Research and Treatment|March 1, 2018
Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-StudyFabienne Schochter, Brigitte Rack, Marie Tzschaschel, et al.
Pageof 105